2 Things That May Boost This Beaten-Down Vaccine Stock
Inovio Pharmaceuticals (NASDAQ: INO) doesn't look like a potential coronavirus-vaccine leader at the moment. The company initially lost momentum when the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on one of its trials last fall.
More recently, the government dropped a plan to fund its phase 3 trial. The U.S. cited the number of vaccines already on the market.
Looks like a dark picture, right? But the story may not be over for Inovio. In fact, there are two things that may offer the company opportunity in the vaccine market. And as a result, they may boost the stock price. Let's take a look at each.
Source Fool.com
